Latest Phase III OA readout boosts Ampio shares

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) added $0.58 (33%) to $2.33 on Thursday after reporting that Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis of the knee.

Read the full 328 word article

User Sign In